Poriferous Secures Patent for DuraBloc Surgical Implant Technology

The DuraBloc technology distinguishes itself by maintaining the porous polyethylene structure characteristic of the company’s Su-Por line while incorporating a smooth, nonporous underside. This dual-sided configuration promotes essential fibrovascular ingrowth for tissue integration, yet simultaneously limits unwanted tissue adhesion. According to the company, this design allows for a 50% lower flange profile, facilitating a more natural aesthetic fit without sacrificing fixation strength.

Aaron Noble, CEO and founder of Poriferous, noted that the innovation directly addresses clinical feedback regarding the complexity of implant removal. By balancing the need for permanent integration with the necessity of future adjustability, the firm intends to streamline procedures for both reconstructive and augmentation cases. The implants remain compatible with antibiotic infusion and retain the material's ability to be trimmed or drilled within the sterile field, ensuring surgeons can adapt the hardware to unique patient anatomy.